AJGP · Volume 55, Issue 10

October 2026: Gender and sexual diversity

Focus issue on caring for LGBTQIA+ people in general practice: mental health, cancer screening, longitudinal and older-age trans care, and reading blood tests on hormone therapy, plus SVT, preeclampsia screening, resistant tinea and more. 18 pieces summarised. Source TOC: RACGP October 2026.

Focus · Clinical #1

The longitudinal primary care of transgender and gender diverse people

Matthew J Ruhl

Argues that ongoing care of trans and gender diverse (TGD) patients should use the same management-planning tools GPs already use for anyone else, with a few tweaks. Frames this care as health-promoting rather than treating a disease. Beyond gender-affirming hormone therapy (GAHT) itself, it flags the areas worth a planned review: cardiovascular risk, mental health, bone health, sexual health, and lifestyle factors like smoking, alcohol, nutrition and activity. Practical takeaway: put TGD patients on a structured chronic-care style plan and recall, rather than seeing GAHT scripts as the whole job.

Focus · Clinical #2

Providing mental healthcare to LGBTQIA+ people in general practice

Darren Russell

LGBTQIA+ Australians carry more psychological distress and mental illness than the general population, explained by the minority stress model (discrimination, stigma, expected rejection, concealment), not by identity itself. Advice for GPs: use affirming language and chosen names and pronouns, do careful and respectful suicide and risk assessment, adapt standard evidence-based therapies, and link people to LGBTQIA+-specialised services where useful. Also notes cost barriers and the need for strict confidentiality. Supportive, affirming GP relationships are associated with less distress and suicidality.

Focus · Clinical #3

Cancer screening in LGBTQIA+ populations

Matthew J Ruhl

LGBTQIA+ people, and TGD people especially, are under-screened for cancer; under 40% of TGD people with a cervix have ever had cervical screening. Because most guidelines ignore these groups, screening is decided by the organs and tissues a person actually has plus their known risk factors (for example, cervical screening for anyone with a cervix, and thinking about breast tissue and prostate after GAHT). Offers individualised assessment, education, self-collection options and inclusive clinic environments as ways to lift participation. Desk use: check your recall system flags screening by anatomy, not recorded sex.

Focus · Clinical #4

The primary care of older transgender and gender diverse people

Ruth McNair, Katie Wynne

Older TGD people often carry a lifetime of discrimination, family rejection, financial and housing insecurity, and past refusals of care, which leaves them with worse physical and mental health and lower screening rates. GPs can start or continue GAHT, refer for surgery, and should watch for conditions that are more common here, such as cardiovascular disease, depression, anxiety and cognitive impairment. Advance care planning gets special emphasis so trusted decision makers are named and gender identity is respected in aged care. Trust built through culturally safe practice is the core tool.

Focus · Clinical #5

Interpretation of blood test results in transgender and gender diverse people undergoing gender-affirming hormone therapy

Brendan J Nolan, Portia Predny

Very practical pathology guide. After about six months on standard-dose GAHT, haemoglobin, haematocrit, red cell count and creatinine move into the range of the affirmed gender, so interpret them against that range to avoid false 'abnormal' flags and needless work-up. Consensus targets quoted: estradiol roughly 250 to 600–1000 pmol/L and total testosterone under 2 nmol/L for estradiol-based therapy, with timing relative to the last dose mattering, and spironolactone may not lower measured testosterone. People on low doses need individual interpretation. Tip: state on the request form which reference range you want reported. Includes a table of Australian GAHT regimens and doses.

CPD #6

October 2026 Clinical challenge

AJGP

The CPD quiz for this issue: multiple-choice and short-answer questions on the Focus articles, worth 10 CPD hours (split between Educational Activities and Reviewing Performance) when completed through gplearning, and auto-logged to myCPD Home. Single articles read on their own can be self-logged for up to two hours each. Suggested Measuring Outcomes project: audit how your practice handles the broader health of TGD patients (cardiovascular, mental, bone and sexual health) using the longitudinal care article as a guide.

Editorial #7

Affirmative care: The heart of general practice

Claire Denness

Introduces the Focus issue and why it is titled 'gender and sexual diversity'. The central message is to treat patients as the experts in their own lives, which explains why assumptions about sexuality or gender cause harm and why asking about names and pronouns and using trauma-informed care matter. Highlights the disparities the issue covers (low cervical screening in TGD people, high rates of mental illness in LGB+ people, high suicidality among older TGD people) and notes that some young TGD patients feel GPs are uncomfortable with them. Ends on the point that affirmative care is ordinary good general practice.

Letters #8

October 2026 correspondence

Paul A Lord; Darran Foo et al; Harriet A Carroll et al; Johanna M Lynch et al

Two exchanges. First, a GP educator challenges an earlier AJGP study rating AI scribes as good as or better than human notes, arguing that notes exist to support clinical reasoning and continuity, not to mirror a transcript, and that trainees may lose reasoning skills if they stop writing notes. The original authors reply that their quality tool was clinician-designed and that scribes record the consult without dictating it. Second, a letter on the earlier coercive control article draws a parallel with patients, often women, being dismissed or told they are 'just anxious' in healthcare, with a response from Lynch and colleagues. Worth reading if you use or are considering an AI scribe.

Clinical #9

Superficial vein thrombosis: A risk-based guide for general practice

Azeez A Kareem, Ameen Gafoor, Mahmoud Al-Najjar

Treats superficial vein thrombosis (SVT) as part of the venous thromboembolism spectrum and gives a risk-based plan. Duplex ultrasound for proximal, atypical or higher-risk cases. Low risk (clot under 5 cm, more than 3 cm from the saphenofemoral or saphenopopliteal junction, no risk factors): symptomatic care. Intermediate risk (5 cm or longer, or 3–5 cm from a junction): prophylactic-dose anticoagulation for 45 days; fondaparinux 2.5 mg daily has the best trial evidence and is PBS listed, while rivaroxaban 10 mg daily (non-inferior in SURPRISE) or enoxaparin are commonly used. High risk (within 3 cm of a junction, propagation, recurrence, thrombophilia or cancer): therapeutic-dose anticoagulation for 3 months (DVT-dose apixaban, rivaroxaban or full-dose low molecular weight heparin). Covers pregnancy and renal impairment, and counselling about recurrence.

Clinical #10

Family experiences, grief and loss after voluntary assisted dying

Hayley Russell, Chien-Che Lin

Part of the voluntary assisted dying (VAD) series, written by community palliative care clinicians. Overseas data suggest families after assisted death may have fewer traumatic grief and post-traumatic stress symptoms than after other deaths, helped by being prepared and able to say goodbye. But GPs should watch for less visible issues: carers' private ambivalence about the decision, stigma or secrecy about how the person died, and complicated grief where risk factors exist. Suggests ways to support meaning-making and continuing bonds, and when to refer to bereavement services.

Clinical #11

Integrating genomics into pre-pregnancy and pregnancy care in general practice: Practical tools from the PRECISE Project

Talia Gusen, Janette Hayward, Mehrnoush Bonakdar Tehrani, Edwina Middleton, Meredith Makeham, Rebecca Chan, Stephen Barnett, Alan Ma, et al

Introduces free resources from the federally funded PRECISE Project to help GPs offer reproductive genetic carrier screening before or early in pregnancy and non-invasive prenatal testing or screening during it. Tools include CPD-accredited modules, point-of-care guides for use mid-consult, and clear referral pathways to genetics services. Also gives simple steps for discussing results, handling uncertainty and coordinating follow-up. Useful if you are unsure which test to offer when, or how to explain a carrier result to a couple.

Clinical #12

Early preeclampsia screening and prevention: An update for general practice

Minh Hang Vu, Daniel L Rolnik, Timothy J Lee

Preeclampsia affects about 1 in 33 Australian pregnancies, and screening on risk-factor checklists alone performs poorly. The authors back a screen-and-treat approach for every pregnant woman using an individual risk calculation, ideally the full Fetal Medicine Foundation (FMF) algorithm in the first trimester (history, blood pressure, uterine artery Doppler and biomarkers), or a limited FMF model where parts are unavailable. Women at high risk should be offered low-dose aspirin, which can cut preterm preeclampsia by up to 62%. Clinic action: make sure early pregnancy work-up gets women into algorithm-based screening in time to start aspirin.

Case study #13

Trichophyton indotineae tinea corporis: The first reported case in Western Australia and its implications for practice

Dasmesh S Sron, Edward Raby, Rachael Foster, Bernadette M Ricciardo

A pregnant woman developed widespread annular scaly plaques after a trip to India; it was first treated as eczema with steroids, then with topical terbinafine and clotrimazole, without improvement, and culture grew T. indotineae. This new dermatophyte is highly terbinafine-resistant and spreading globally, fuelled by over-the-counter steroid and antifungal combination creams. Lessons: take a skin scraping before treating doubtful or resistant tinea, check scalp and nails, and when T. indotineae is suspected use itraconazole (SUBA itraconazole 100 mg twice daily preferred) with a trough level at 10–14 days and treatment until clinical and mycological cure. The case also covers the extra care needed in pregnancy and breastfeeding.

Research #14

Barriers to obesity management in primary care: Financial and time constraints

Talia Palacios, Terri-Lynne South, Andrea Jasper, Carly Barlow, Ramesh Manocha, Nuria Zamora Solano, Emily Gibson, Samantha Hocking

National survey of 943 GPs (late 2023 to early 2024). Most give diet and lifestyle advice and over half often raise weight, but only about 1 in 8 had formal obesity training. Main barriers were poor Medicare rebates for long weight consults, unaffordable obesity medicines, inadequate chronic disease plans, competing priorities and lack of time. GPs wanted better MBS funding, PBS-subsidised obesity drugs, better public hospital access and more training. Supports advocacy and is a prompt to look at the Australian Obesity Management Algorithm.

Research #15

A qualitative study on the practicality of guideline recommended office blood pressure measurement in primary care

James E Sharman, Laura Sutton, Annika Wilson, Sarah Prior, Mark R Nelson, et al

Tasmanian co-design workshops with 63 primary care clinicians and 47 community members. Clinicians knew the proper protocol (seated, back and arm supported, cuff at heart level, 3–5 minutes' rest, two or more readings averaged, no talking, at least 10 minutes in total), yet none followed it strictly, citing time and competing priorities, and no community member recalled ever having it done. The authors conclude the guideline method is impractical in routine consults, which matters because sloppy readings misclassify risk. Food for thought: delegate standardised or automated unattended readings, or lean more on home and ambulatory monitoring.

Professional #16

Care at the end of life: What really matters to people?

Katherine Clark, Wei Lee, Abbie Franklin, Sara Townend, David Currow

Part of the VAD series. Lists what dying people say matters most: good control of pain and breathlessness, honest communication and relationships with clinicians, spiritual and emotional needs, control over treatment decisions and place of death without needless prolonging of life, enough information to know what to expect, family support, not being a burden, and for some, choosing the timing of death. Argues that death has become over-medicalised and hospital-based, often against people's wishes, and that GPs' long relationships put them in the best spot for timely conversations and documented care plans.

Professional #17

Optimising a culture of learning with peer-led small group learning sessions

Anna Sallos, Shaun Prentice, Penny Need, Annette Burgess

Describes the small group learning sessions at the centre of the RACGP's national GP training program, now that training has moved from regional organisations to the college. Stable groups of registrars meeting regularly, with a medical educator facilitating, build trust, allow honest reflection on real cases, give peer benchmarking and strengthen professional identity. Good first-meeting 'scene setting', mutual sharing and skilled facilitation help most. Relevant mainly if you supervise registrars or run a peer group or Balint-style meeting.

ReCEnT #18

Evidence to inform practice: General practice registrars’ imaging for non-specific low back pain

Tobias Morgan, Parker Magin

Short summary of ReCEnT registrar data from 2010–18: non-specific low back pain was 0.6% of problems seen, and 15% of first presentations had imaging ordered. Imaging was more likely with older patients, when the registrar sought supervisor advice, booked follow-up with themselves, or set a learning goal, which suggests thoughtful rather than reflex ordering, though rates probably exceed optimal levels. The authors suggest guideline red flags may need refining to target imaging better. Reminder: most back pain in general practice is benign and self-limiting; image only for genuine red flags.